CLPT
ClearPoint Neuro, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- S May 20 1 insider sell $56.7K at $11.14
- S Jun 1 1 insider sell $65.9K at $12.17
- S Jun 17 1 insider sell $1.1M at $17.79
- S Jun 29 1 insider sell $387.6K at $19.38
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $1.6M.
- InstitutionsMIXED
Q2 2026: 12 added (0 new), 9 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$0.263 → −$0.315 over 90 days. 0 up, 3 down in 30 days.
- Short sellersSTEADY
Short interest −2.8% to 4.63M shares. 6.6 days to cover, ≈15.2% of shares.
- TrendDOWNTREND
24% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC | ADD | $6.4M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | $4.3M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | TRIM | $3.5M |
| MORGAN STANLEY | ADD | $3.0M |
| GOLDMAN SACHS GROUP INC | TRIM | $2.5M |
| DEUTSCHE BANK AG\ | TRIM | $2.0M |
| Quantinno Capital Management LP | ADD | $1.4M |
| IMC-Chicago, LLC | TRIM | $472.7K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Jun 2026Price is below the lowest target. Median implies +143%.Targets as of Oct 28, 2026.
| Date | Firm | Rating |
|---|---|---|
| Jun 18, 2026 | B. Riley Securities MAINTAIN | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 1, 2026 | Richards Timothy T. Director | AWARD | $3.9K |
| Oct 1, 2026 | FLETCHER R JOHN Director | AWARD | $12.1K |
| Sep 2, 2026 | BURNETT JOSEPH CEO and President | EXERCISE | $43.4K |
| Jul 1, 2026 | FLETCHER R JOHN Director | AWARD | $11.8K |
| Jul 1, 2026 | Richards Timothy T. Director | AWARD | $4.0K |
| Jun 30, 2026 | STIGALL L. JEREMY Chief Business Officer | AWARD | $21.2K |
| Jun 30, 2026 | D'Alessandro Danilo Chief Financial Officer | AWARD | $12.9K |
| Jun 30, 2026 | BURNETT JOSEPH CEO and President | AWARD | $16.2K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.32 | -$0.36–-$0.27 | +0.0% | $12.3M |
| Next Q | -$0.29 | -$0.34–-$0.25 | +0.0% | $13.7M |
| Current FY | -$1.30 | -$1.39–-$1.22 | +0.0% | $49.0M |
| Next FY | -$1.20 | -$1.23–-$1.16 | +0.0% | $56.5M |
Short side
FINRA· Oct 15, 2026SecBot reports
3 filings · 0 bullish · 0 bearish · 1 mixed · 2 neutral- NEUTRAL 8-KMay 21, 2026
ClearPoint Neuro held its 2026 annual meeting on May 20, 2026. Stockholders approved the Seventh…
Routine annual meeting results — no trading signal. Monitor future equity grant disclosures under the new plan to gauge actual dilution run-rate.
- NEUTRAL 144May 20, 2026
Director Lynnette C. Fallon filed a Form 144 to sell 5,091 shares of ClearPoint Neuro common…
Insider sale is small and routine, likely for tax purposes after RSU vesting. No signal of deteriorating fundamentals. Monitor for any larger insider selling patterns or changes in executive turnover.
- MIXED 8-KMay 13, 2026
ClearPoint Neuro reported Q1 2026 revenue of $12.1M (+43% YoY), beating pre-release consensus? (no…
Strong top-line growth and margin expansion are positives, but widening losses and cash burn persist. Guidance unchanged suggests management is confident in H2 improvements from IRRAS synergies…
All CLPT filing & press-release reports (3)
- 8-K reportMay 21, 2026
- 144 reportMay 20, 2026
- 8-K reportMay 13, 2026